Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, has named former OBG Pharmaceuticals Chief Scientific Officer Andrew Brown as CEO, succeeding Glyn Taylor, who will continue part time as Chief Scientific Officer.
Brown was most recently Chief Scientific Officer and Operations Director of OBG subsidiary Noveayr Therapeutics, which closed earlier this year, and was previously General Manager of OBG subsidiary Pharmaserve NW and served in various roles at Oriel Therapeutics, GSK, and Sanofi-Aventis.
In addition to providing OINDP analytical and development services and lung deposition studies, Cardiff / i2c developed the Respitab MDI filling technology in which the drug is introduced into the canister as a tablet which dissolves or disperses when the can is filled with propellant. In 2021, Aptar Pharma announced that it would co-develop the Respitab technology.
Brown commented, “I am honored to lead such a talented team at CSL/i2c during this pivotal time. CSL/i2c’s unique offering and strong IP provide a great platform for future growth.”
Taylor said, “Andrew is clearly an inspiring person with the qualities and experience to lead CSL/i2c through the next phase of the company’s expansion and he has the unanimous support of the board.”
Read the Cardiff Scintigraphics press release.
